ReviewOncology reports2026
Advances in the application of frailty scoring in the diagnosis and management of elderly patients with multiple myeloma (Review).
Review in Oncology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple myeloma (MM) is a hematological malignancy that disproportionately affects elderly populations, with age being a key risk factor for disease progression and adverse outcomes. Frailty, a multifaceted geriatric syndrome characterized by reduced physiological reserve and increased vulnerability to stressors, is recognized as a pivotal factor influencing the diagnosis, prognosis and therapeutic management of elderly patients with MM. The present review explores the complex interplay between frailty and MM, discussing the underlying mechanisms, such as chronic inflammation, sarcopenia and immune dysfunction, that link these conditions. In addition, the clinical implications of frailty, including its association with higher treatment toxicity, prolonged hospitalization and diminished survival rates, are reviewed. The present study also aimed to evaluate commonly used frailty assessment tools, such as the International Myeloma Working Group frailty score and the Geriatric Assessment, and their use in guiding clinical decision‑making. Recent advancements in frailty scoring systems, which enable more precise risk stratification, are highlighted, emphasizing their role in tailoring individualized treatment strategies to balance efficacy and safety. Finally, the present review addresses current challenges in integrating dynamic frailty monitoring into routine clinical practice and outlines future directions, including the development of novel biomarkers and digital tools to enhance frailty assessment and improve long‑term patient outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.